In the latest trading session, 0.49 million Phathom Pharmaceuticals Inc (NASDAQ:PHAT) shares changed hands as the company’s beta touched 0.63. With the company’s most recent per share price at $5.96 changing hands around $0.38 or 6.81% at last look, the market valuation stands at $407.53M. PHAT’s current price is a discount, trading about -230.7% off its 52-week high of $19.71. The share price had its 52-week low at $5.21, which suggests the last value was 12.58% up since then.
Analysts gave the Phathom Pharmaceuticals Inc (PHAT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.22. If we narrow down to specifics, the data shows that 2 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended PHAT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Phathom Pharmaceuticals Inc’s EPS for the current quarter is expected to be -1.08.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Instantly PHAT is in green as seen in intraday trades today. With action 3.47%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -26.60%, with the 5-day performance at 3.47% in the green. However, in the 30-day time frame, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is -9.15% down.
The consensus price target for the stock as assigned by Wall Street analysts is 27, meaning bulls need an upside of 77.93% from its recent market value. According to analyst projections, PHAT’s forecast low is 12 with 35 as the target high. To hit the forecast high, the stock’s price needs a -487.25% plunge from its current level, while the stock would need to soar -101.34% for it to hit the projected low.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Year-over-year growth is forecast to reach 7,414.06% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 25.65M. 4 analysts are of the opinion that Phathom Pharmaceuticals Inc’s revenue for the current quarter will be 28.54M. The company’s revenue for the corresponding quarters a year ago was 682k and 1.91M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3,661.58%. The estimates for the next quarter sales put growth at 1,392.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -137.06%. The 2025 estimates are for Phathom Pharmaceuticals Inc earnings to decrease by -34.71%, but the outlook for the next 5-year period is at 22.16% per year.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD holds the second largest percentage of outstanding shares, with 12.7473% or 7.46 million shares worth $76.89 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Invesco Global Fund and PGIM Jennison Health Sciences Fd. With 1.98 shares estimated at $11.55 million under it, the former controlled 2.89% of total outstanding shares. On the other hand, PGIM Jennison Health Sciences Fd held about 2.61% of the shares, roughly 1.78 shares worth around $10.41 million.
